MADISON HEIGHTS, Mich., July 21, 2015 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, announced today the rollout of InfuSystem EXPRESS, the Company's patent-pending EMR connectivity solution, at the University of California - San Diego Moores Cancer Center.
"Powered by our InfuBus™ connectivity engine, InfuSystem EXPRESS delivers on our promise of Infusion Made Easy," said Eric K. Steen, chief executive officer of InfuSystem. "EXPRESS securely integrates with UC-San Diego Health System's Epic electronic medical software system to automatically deliver data, improving efficiency, reducing transcription errors, and eliminating insurance paperwork associated with oncology patients going home on our infusion pumps. We believe medical facilities, like those of the UC-San Diego Health System, will find our portfolio of connectivity offerings to be a valuable resource. EXPRESS utilizes a smart data listener and extractor for identifying and integrating the right patient and pump information needed for insurance claims while remaining secure and HIPAA-compliant."
InfuSystem EXPRESS immediately improves a practice's workflow by automating the daily processes associated with treatment logs and pump assignments, as well as tracking and standardizing data flow at practices with multiple locations. In addition to facilities using Epic, InfuSystem EXPRESS integrates with Varian, Altos and other popular electronic medical record (EMR) management systems at sites nationwide.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. The Company's stock is traded on the NYSE MKT under the symbol INFU. Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including rates, payor mix and CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on our Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. regulatory changes and healthcare reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2014. Our annual report on Form 10-K is available on the SEC's EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements.
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
SOURCE InfuSystem Holdings, Inc.